H-CYTE, Inc. (HCYT)

OTCMKTS: HCYT · Delayed Price · USD
0.0240
0.0000 (0.00%)
May 18, 2022 12:57 PM - Market open
Market Cap6.12M
Revenue (ttm)1.61M
Net Income (ttm)-4.80M
Shares Out255.09M
EPS (ttm)-0.03
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume4,000
Open0.0240
Previous Close0.0240
Day's Range0.0240 - 0.0240
52-Week Range0.0100 - 0.2890
Beta1.35
AnalystsSell
Price Targetn/a
Earnings DateMay 11, 2022

About HCYT

H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.

IndustryBiotechnology
Employees8
Stock ExchangeOTCMKTS
Ticker SymbolHCYT
Full Company Profile

Financial Performance

In 2021, H-CYTE's revenue was $1.61 million, a decrease of -25.07% compared to the previous year's $2.15 million. Losses were -$4.80 million, -25.70% less than in 2020.

Financial Statements

News

H-CYTE Announces Proceeds of $1.05 Million from Warrant Exercise

Proceeds to Support Inorganic Growth and General Working Capital Purposes Proceeds to Support Inorganic Growth and General Working Capital Purposes

2 months ago - GlobeNewsWire

H-CYTE Enters Into Letter of Intent for Acquisition of Catheter Precision, Inc.

Targets one of Healthcare's Largest Multi-Billion Dollar Markets: Cardiac Electrophysiology Targets one of Healthcare's Largest Multi-Billion Dollar Markets: Cardiac Electrophysiology

4 months ago - GlobeNewsWire